Updated Jul 16, 2026
Turtle Cameron has filed 3 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $5.31M.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-03 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 590 | $88.91 | $52K |
| 2026-07-03 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 4.2K | $88.12 | $373K |
| 2026-07-03 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 10.2K | $87.44 | $890K |
| 2026-06-04 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 3.3K | $71.38 | $235K |
| 2026-06-04 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 8.1K | $70.50 | $575K |
| 2026-06-04 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 3.6K | $69.40 | $247K |
| 2026-05-02 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 300 | $74.96 | $22K |
| 2026-05-02 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 1.7K | $74.23 | $126K |
| 2026-05-02 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 3.1K | $73.14 | $227K |
| 2026-05-02 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 1.0K | $71.76 | $72K |
| 2026-05-02 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 3.6K | $70.77 | $255K |
| 2026-05-02 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 5.3K | $69.54 | $369K |
| 2026-04-04 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale [10b5-1] | 2.7K | $49.92 | $133K |
| 2026-04-04 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale [10b5-1] | 12.3K | $49.20 | $607K |
| 2026-03-04 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale [10b5-1] | 9.1K | $42.49 | $387K |
| 2026-03-04 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale [10b5-1] | 5.9K | $41.73 | $246K |
| 2026-02-05 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale [10b5-1] | 14.0K | $32.87 | $462K |
| 2026-02-05 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale [10b5-1] | 957 | $31.82 | $30K |
Turtle Cameron is a corporate insider — currently tracked as Chief Executive Officer, Director of Spyre Therapeutics, Inc. (SYRE). InsiderAlpha tracks every SEC Form 4 filing in real time.
3 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 18 open-market sales ($5.31M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Turtle Cameron profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.